Research Article

Afatinib Targeted Therapy Affects the Immune Function and Serum Levels of EGFR and Gastrin-Releasing Peptide Precursor (pro-GRP) in Patients with Non-Small-Cell Lung Cancer (NSCLC)

Table 1

Comparison of the general information of the two groups of included patients.

GroupCaseGender (male/female)Age (year)BMI (kg/m2)ASA grade
AdenocarcinomaAdenosquamous carcinoma

Treatment group A4224/182022
Treatment group B4426/182321
0.1460.2650.3650.437
0.7960.6450.5680.567